Clinical Trial Update: A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial of Efruxifermin in non-cirrhotic Nonalcoholic Steatohepatitis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-08